Table 5.
Detailed ELISpot data for tested HLA B*07:02 patientsb
| Peptide | Patient no., HIV statusa |
Responses/tested | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2044, NSN | 2230, NSN | 2181, POS | 2127, NSN | 1961, NSN | 2035, NSN | 1394, RES (HESN) | 2257, POS | 2427, POS | 2320, NSN | 2400, POS | 2545, POS | 2619, POS | 2423, NSN | 2425, NSN | 2644, NSN | ||
| APPAEIFGM | 0 | 0 | 100 | 0 | 5 | 0 | 10 | 20 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/8 |
| APRKKGCWK | 35 | 240 | 0 | 0 | 0 | 20 | 55 | 0 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 2/8 |
| FPQSRPEPT | 0 | N/T | 25 | 55 | 35 | 0 | 0 | 0 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/7 |
| GPGATLEEM | 0 | N/T | N/T | 80 | 25 | 35 | N/T | 45 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| GPGHKARVL | 90 | 0 | 0 | 5 | 0 | 0 | 75 | 30 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 2/8 |
| GPIPPGQMR | 0 | N/T | N/T | 15 | 10 | 0 | N/T | 215 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| GPSHKARVL | 55 | 0 | 5 | 65 | 20 | 65 | 0 | 10 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 3/8 |
| RALGPGATL | 0 | N/T | N/T | 175 | 80 | 0 | N/T | 90 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 3/5 |
| RLRPGGKKK | 0 | N/T | N/T | 135 | 10 | 35 | N/T | 20 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| RPGNFPQSR | 0 | N/T | N/T | 0 | 0 | 0 | N/T | 80 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| SPRTLNAWV | 115 | 375 | 0 | 0 | 35 | 0 | 25 | 20 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 2/8 |
| TPQDLNMML | 0 | N/T | N/T | 15 | 30 | 0 | N/T | 905 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| TPQEQIGWM | 0 | N/T | N/T | 0 | 20 | 10 | N/T | 185 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/5 |
| TPQEQLGWM | 0 | N/T | N/T | 0 | 35 | 0 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 0/4 |
| VRMYSPVSI | 0 | N/T | N/T | 435 | 0 | 0 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 1/4 |
| WPSSKGRPG | 70 | 220 | 0 | 0 | 0 | 55 | 25 | 5 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 3/8 |
| YPLVSLKSL | 0 | 0 | 1320 | 85 | 30 | 0 | 10 | 40 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 2/8 |
| YVDRFFKTL | 0 | 0 | 2500 | 60 | 40 | 0 | 10 | 15 | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 2/8 |
| GPGHKARVL | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 55 | 75 | 70 | 45 | 5 | 5 | 15 | 135 | 4/8 |
| GPSHKARVL | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 70 | 67 | 70 | 55 | 15 | 70 | 10 | 235 | 6/8 |
| KARVLAEAM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 45 | 50 | 80 | 75 | 0 | 115 | 10 | 70 | 5/8 |
| QVQHTNIMM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 45 | 55 | 95 | 75 | 5 | 80 | 50 | 165 | 6/8 |
| QAQQPNVMM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 65 | 30 | 70 | 70 | 0 | 10 | 50 | 225 | 5/8 |
| QVNGNTAIM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 65 | 50 | 80 | 90 | 5 | 120 | 5 | 190 | 6/8 |
| QANANTAIM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 75 | 25 | 65 | 80 | 5 | 115 | 55 | 265 | 6/8 |
| ATNANAAIM | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 60 | 60 | 85 | 75 | 15 | 25 | 5 | 195 | 5/8 |
| NIMMQRGNF | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 35 | 25 | 80 | 50 | 10 | 0 | 10 | 170 | 3/8 |
| NIMMQRSNF | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 65 | 70 | 125 | 50 | 5 | 105 | 15 | 310 | 6/8 |
| NVMMQRSNF | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 55 | 90 | 85 | 100 | 5 | 55 | 15 | 315 | 6/8 |
| AIMMQRGNF | N/T | N/T | N/T | N/T | N/T | N/T | N/T | N/T | 90 | 35 | 35 | 65 | 0 | 80 | 30 | 215 | 4/8 |
a
RES (HESN), HIV-1 resistant; POS, HIV-1 positive; NSN, newly enrolled seronegative; N/T, not tested.
b
Bold patient numbers indicate that fresh PBMCs were used. Lightface patient numbers indicate that PBMCs were previously frozen and stored in liquid nitrogen.